Alzheimer’s: New Blood Test Predicts Symptom Onset Years in Advance
A new model developed by researchers at Washington University School of Medicine in St. Louis offers a potential breakthrough in Alzheimer’s disease prediction. The model estimates when a person is likely to begin experiencing symptoms of Alzheimer’s using a single blood test, representing a less invasive and more accessible alternative to current diagnostic methods.
A New Approach to Alzheimer’s Prediction
Published February 19 in Nature Medicine, the research indicates the model can forecast the onset of symptoms within approximately three to four years. This level of accuracy could significantly accelerate and refine clinical trials focused on preventative treatments. Over time, it may also help identify individuals who stand to benefit most from early interventions.
The Burden of Alzheimer’s Disease
More than 7 million Americans currently live with Alzheimer’s disease. The Alzheimer’s Association projects the cost of care for those with Alzheimer’s and other dementias will reach nearly $400 billion by 2025. While a cure remains elusive, tools that can anticipate symptom onset could play a crucial role in mitigating the disease’s impact.
The Role of p tau217
The predictive model centers on measuring p tau217, a protein found in plasma – the liquid component of blood. By analysing levels of this protein, researchers estimate the age at which someone may begin to experience Alzheimer’s symptoms. Currently, p tau217 testing aids in diagnosing Alzheimer’s in patients already exhibiting cognitive impairment, but is not generally recommended for those without symptoms outside of research settings.
Data from Long-Running Studies
To understand the timeline between rising p tau217 levels and symptom appearance, Suzanne E. Schindler, MD, PhD, and Kellen K. Petersen, PhD, examined data from 603 older adults. Participants were enrolled in two ongoing studies: the WashU Medicine Knight Alzheimer Disease Research Center (Knight ADRC) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), which spans multiple research sites across the U.S.
Testing and Validation
Plasma p tau217 was measured using PrecivityAD2, a clinically available test developed by C2N Diagnostics – a WashU startup – in the Knight ADRC group. The ADNI group utilized tests from other companies, including one approved by the U.S. Food and Drug Administration. Previous research has established that plasma p tau217 levels correlate with amyloid and tau buildup in the brain, hallmarks of Alzheimer’s disease that can accumulate years before cognitive decline becomes apparent.
Predicting the Timeline
Researchers found their model could estimate symptom onset within a three-to-four-year margin. Age influenced the speed at which symptoms followed elevated p tau217 levels; older adults tended to develop symptoms sooner than younger individuals. This suggests that younger brains may exhibit greater resilience to disease-related changes, while older brains may show symptoms at lower levels of underlying pathology. For example, a person with rising p tau217 levels at age 60 might develop symptoms around age 80, while someone with rising levels at age 80 might develop symptoms around age 91.
The model’s performance remained consistent across different p tau217-based diagnostic tests, reinforcing its reliability. The team has made the model’s code publicly available and created a web-based application for researchers to explore the data further.
Frequently Asked Questions
What is p tau217?
p tau217 is a protein found in plasma, the liquid component of blood. Researchers are using it to estimate when a person may begin experiencing Alzheimer’s symptoms.
How accurate is this new model?
The model can forecast the onset of Alzheimer’s symptoms within a margin of about three to four years.
Where can I find more information about the research?
The study was published in Nature Medicine on February 19, 2026, and is available through the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database at adni.loni.usc.edu.
As research continues, these “clock models” could become increasingly refined, potentially paving the way for personalized predictions of symptom onset and more effective strategies for preventing or slowing the progression of Alzheimer’s disease.